Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index; 16 of the 62 sources its claims cite were checked for support.
Abstract
Elimination of amyloid-ss peptide (Ass) from the brain is poorly understood. After intracerebral microinjections in young mice, (125)I-Ass(1-40) was rapidly removed from the brain (t(1/2) </= 25 minutes), mainly by vascular transport across the blood-brain barrier (BBB). The efflux transport system for Ass(1-40) at the BBB was half saturated at 15.3 nM, and the maximal transport capacity was reached between 70 nM and 100 nM. Ass(1-40) clearance was substantially inhibited by the receptor-associated protein, and by antibodies against LDL receptor-related protein-1 (LRP-1) and alpha(2)-macroglobulin (alpha(2)M). As compared to adult wild-type mice, clearance was significantly reduced in young and old apolipoprotein E (apoE) knockout mice, and in old wild-type mice. There was no evidence that Ass was metabolized in brain interstitial fluid and degraded to smaller peptide fragments and amino acids before its transport across the BBB into the circulation. LRP-1, although abundant in brain microvessels in young mice, was downregulated in older animals, and this downregulation correlated with regional Ass accumulation in brains of Alzheimer's disease (AD) patients. We conclude that the BBB removes Ass from the brain largely via age-dependent, LRP-1-mediated transport that is influenced by alpha(2)M and/or apoE, and may be impaired in AD.
Overview
CoChat Summary
TL;DR
In mice, intracerebrally injected ¹²⁵I-Aβ1-40 is rapidly cleared from brain, mainly by LRP-1-mediated transport across the blood-brain barrier, with clearance influenced by α2M and apoE. LRP-1 downregulation in older mice and in Alzheimer’s disease brain regions correlates with Aβ accumulation, suggesting impaired vascular clearance may contribute to AD.
Key findings
- After intracerebral microinjection in young mice, total brain efflux half-time for ¹²⁵I-Aβ1-40 was 25.5 ± 2.0 minutes versus 239.0 ± 12.5 minutes for [¹⁴C]inulin (9.4-fold difference); BBB transport accounted for 73.8% of efflux, ISF bulk flow 10.7%, and 15.6% remained retained at 60 nM.
- Aβ1-40 clearance was concentration-dependent, half-saturated at 15.3 nM, and maximal between 70 nM and 100 nM. Anti-LRP-1 antibody inhibited clearance by about 55% (58% at 12 nM and 53% at 60 nM), RAP inhibited by 30–44%, and anti-α2M inhibited by 25%; anti-LRP-2 and anti-RAGE had no effect.
- There was no evidence of significant Aβ1-40 degradation in brain ISF before transport: injected peptide was >97% intact, 93.7% remained intact at 60 minutes, and only 4.2–9.9% of brain ¹²⁵I radioactivity was non-TCA-precipitable within 270 minutes; plasma degradation increased from 37.6% to 58.3% between 15 and 120 minutes.
- Clearance was reduced in apoE knockout and older mice: 30% reduction in young apoE KO mice, about 55% and 40% reductions in 9-month-old wild-type and apoE KO mice at 12 nM, and 46% reduction in 9-month-old apoE KO mice at 60 nM. LRP-1-positive brain vessels dropped from 94% in 2-month-old mice to 52% in 9-month-old mice, and reduced LRP-1 staining in AD frontal cortex correlated with regional Aβ accumulation.
Methods
- Male C57BL/6 wild-type and apoE knockout mice at 8–10 weeks and 9–10 months received intracerebral microinjections into the right caudate nucleus of ¹²⁵I-Aβ1-40 (0.05–120 nM) plus [¹⁴C]inulin; clearance was measured from 10 to 300 minutes, with dose and inhibitor studies at 30 minutes.
- Radioactivity was analyzed by TCA precipitation, HPLC, and SDS-PAGE; compartmental modeling separated BBB transport, ISF bulk flow, and brain retention. Inhibitors included anti-LRP-1 R777, RAP, anti-α2M, anti-LRP-2, anti-RAGE, fucoidin, and BCH.
- Immunocytochemistry was performed in mouse brain and human frontal cortex/cerebellum from 3 AD patients and 3 age-matched controls (postmortem 4–7 hours), using antibodies against LRP-1, α2M, Aβ1-40/1-42, and CD105.
Limitations
- The paper does not state limitations explicitly. Evident from the text: the mouse clearance model uses synthetic ¹²⁵I-Aβ1-40 and intracerebral injection, which may not fully reflect endogenous Aβ production and clearance.
- Evident: human data are correlational and based on only 3 AD patients and 3 controls; LRP-1 involvement is inferred from antibody/RAP inhibition and immunostaining rather than direct transport assays.
- Evident: the identity of an alternative low-concentration BBB transport mechanism remains unknown, α2M staining cannot distinguish circulating from microvessel-associated α2M, and age comparisons are limited to young versus 9-month-old mice.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 0 Not valid · 21 Not checked · 114 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Previous studies from our laboratory and others have demonstrated a major role of the BBB in determining the concentrations of A b in the CNS by regulating transport of circulating A b (33, 39, 49-51, 62-66).”
What the sources say
- Partly supportedcites [33] Mackic, 1998, J Clin Invest sourceExperimental — accuracy not yet measured
The Discussion reports transport of circulating Aβ across a human BBB cell model and says that this transport would tend to increase Aβ accumulation in the brain. It does not demonstrate that the BBB has a major role in determining CNS Aβ concentrations in vivo; the paper describes that broader implication as likely. Page numbers are unavailable in our copy. (LLM, conf=0.84)
- Partly supportedcites [39] Zlokovic, 1996, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The paper’s opening summary (page not specified in our copy) reports transport of Aβ–apolipoprotein J complexes across the blood–brain barrier into brain tissue in a guinea pig model. It does not establish that this transport has a major role in determining overall CNS Aβ concentrations, as the citing sentence claims. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [49] Maness, 1994, Life Sci source
- Not checked — no full text of the sourcecites [50] Poduslo, 1997, Neurobiol Dis source
- Not checked — no full text of the sourcecites [51] Martel, 1997, J Neurochem source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Binding/uptake studies in mouse embryonic fibroblasts (wild type and deficient in LRP-1), confirmed that free A b is not a ligand for LRP-1 (37, 45).”
What the sources say
- Partly supportedcites [37] Narita, 1997, J Neurochem sourceExperimental — accuracy not yet measured
The Abstract and Discussion report that free Aβ degradation was not inhibited by RAP and describe it as LRP-independent. But Table 1 tested free Aβ in human U87 glioblastoma cells; the mouse embryonic fibroblast comparison tested Aβ complexed with α2-macroglobulin, not free Aβ. Thus the paper supports the LRP-independent uptake conclusion, but not the claim that the fibroblast studies confirmed it. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [45] Kounnas, 1995, Cell source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Because normal aging is associated with A b accumulation in the brain (1)”
What the sources say
- Supportedcites [1] Wisniewski, 1997, Neurobiol Dis source
The section on the amyloid cascade hypothesis says that extensive Aβ-containing preamyloid deposits can be found in aged individuals with no reported clinical symptoms. This supports the claim that brain Aβ accumulation is associated with normal aging; the paper does not say it occurs in every older person. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This makes re-entry of radiolabeled A b into the brain very unlikely, because the blood-to-brain transport of A b normally operates down the concentration gradient (39, 62-65).”
What the sources say
- Partly supportedcites [39] Zlokovic, 1996, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The paper’s study summary (page not identified in our copy) reports transport of Aβ–apolipoprotein J complexes from blood into brain parenchyma. It does not say that this transport normally follows a concentration gradient or that re-entry of radiolabeled Aβ is unlikely. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [62] Zlokovic, 1993, Biochem Biophys Res Commun source
- Not checked — no full text of the sourcecites [63] Ghilardi, 1996, Neuroreport source
- Not checked — no full text of the sourcecites [64] Shayo, 1997, Life Sci source
- Partly supportedcites [65] Martel, 1996, Neurosci Lett sourceExperimental — accuracy not yet measured
The discussion passage in our copy (labeled Abstract; page unavailable) says that a lower soluble Aβ42 concentration on the brain side of the BBB would provide a thermodynamic impetus for transport from capillaries into brain. It does not establish that blood-to-brain transport normally operates down a concentration gradient or that re-entry of radiolabeled Aβ is very unlikely; the study also observed uptake of radiolabeled Aβ in perfused guinea-pig brains. (LLM, conf=0.80)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“RAP, a chaperone protein that facilitates proper folding and subsequent trafficking of LRP-1 and LRP-2 (69), also inhibited A b clearance.”
What the sources say
- Partly supportedcites [69] Bu, 1996, J Biol Chem sourceExperimental — accuracy not yet measured
The citation is attached to the description of RAP as a folding and trafficking chaperone, not to the citing authors’ statement that RAP inhibited Aβ clearance. The paper’s Discussion supports that role for LRP, but does not establish it for the separate receptor LRP-2; its use of “LRP2” denotes a domain of LRP. (LLM, conf=0.89)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
92 more claims
Create a free account to see all 147 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 30
- Probably not a substantial claim. 25
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“For example, transport studies using radiolabeled and unlabeled Alzheimer's A 𝛃 peptide have shown that under physiological conditions, the perivascular ISF flow contributes to 15-20% of A 𝛃 clearance from the mouse brain (58, 535, 659), whereas 8085% is removed by transvascular BBB transport.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 binds Alzheimer's A 𝛃 toxin and mediates its brain-to-blood clearance (58, 137, 535, 561).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several groups have reported that trans-BBB efflux of Aβ into peripheral blood circulation is one of the main pathways of physiological clearance with ApoE, ApoJ, and ApoA1 as chaperones27,31,32.”
From Brain-targeted drug delivery by manipulating protein corona functions (2019) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 and LRP2 are expressed in brain endothelium and colocalize mainly on the abluminal side of the BBB in humans and rodents (137, 404, 535, 607, 682).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“whereas 8085% is removed by transvascular BBB transport.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results · p. 5
“The HPLC analysis of brain radioactivity confirmed the TCA results by indicating that 93.7% of the peptide remains intact in brain ISF at 60 minutes (Figure 3b, right).”
§ Figure 3 · p. 6
“( b ) Left panel shows HPLC elution profile of brain tissue 60 minutes after intracerebral microinjection of 125 I-A b 1-40 (60 nM). Separation was performed for 30 mg of brain tissue on a reverse-phase HPLC column, using a 30-minute linear gradient of 25-83% acetonitrile in 0.1% TFA, pH 2. 125 I-A b 1-40 eluted at 52%, corresponding to the elution time of A b 1-40 standard. Right panel shows SDS-PAGE analysis”
Citations
Cites
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · cited 10×
“No anti-Aβ1-40–positive or Aβ1-42–positive staining was seen in either AD or control tissues.”
BackgroundInfluentialCorrelative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · cited 2×
“Because normal aging is associated with Aβ accumulation in the brain (1), and there is a significant, timedependent, and progressive accumulation of the peptide with age in transgenic APP animals (54, 55), we postulated that Aβ clearance mechanisms might be impaired in older animals, and are also possibly impaired in…”
BackgroundRAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 9×
“In contrast, anti–LRP-2 Ab (Figure 4b) and anti-RAGE Ab (Figure 4c) did not affect Aβ clearance.”
BackgroundInfluentialIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
BackgroundSelf-citationHolcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386 · cited 1×
“Because normal aging is associated with Aβ accumulation in the brain (1), and there is a significant, timedependent, and progressive accumulation of the peptide with age in transgenic APP animals (54, 55), we postulated that Aβ clearance mechanisms might be impaired in older animals, and are also possibly impaired in…”
BackgroundAlzheimer's Disease--Genotypes, Phenotype, and Treatments
Selkoe, D. J. (1997) · Science · doi:10.1126/science.275.5300.630 · Cited by 875 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
BackgroundIwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.-J., Hama, E., Sekine-Aizawa, Y., et al. (2000) · Nature Medicine · doi:10.1038/72237 · Cited by 867 · cited 8×
“However, the physiological relevance of the proposed degradation mechanism for Aβ1-42 (28) remains unclear, because the peptide was studied at extremely high concentrations (∼ 240 μM) that are not found even in brains with severe β-amyloidosis (30).”
BackgroundMethodResultInfluentialThe cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease
Selkoe, D. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01363-4 · Cited by 862 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
Background
Research works printed but not linked: 4
- Suzuki, 1994, Am J Pathol, 145, 452
- Urmoneit, 1997, Lab Invest, 77, 157
- Yamada, 1991, Am J Physiol, 261, H1197
- Kounnas, 1994, In Vivo, 8, 343
Cited by
Items 201–300 of 1,448
Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis
Carro, E., Trejo, J. L., Gerber, A., Loetscher, H., Torrado, J., Metzger, F., & Torres-Aleman, I. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.06.015 · Cited by 178
“: +34 91 585 4723; fax: +34 91 585 4754.”
Ji, Z.-S., Miranda, R. D., Newhouse, Y. M., Weisgraber, K. H., Huang, Y., & Mahley, R. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112109200 · Cited by 177
Louveau, A., Da Mesquita, S., & Kipnis, J. (2016) · Neuron · doi:10.1016/j.neuron.2016.08.027 · Cited by 177
“tein receptor-related protein 1 (LRP1) by the vascular endothelial cells (Erickson et al., 2012; Hartz et al., 2016; Shibata et al., 2000).”
Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review
Dinda, B., Dinda, M., Kulsi, G., Chakraborty, A., & Dinda, S. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.03.009 · Cited by 174
Brain Meets Body: The Blood-Brain Barrier as an Endocrine Interface
Banks, W. A. (2012) · Endocrinology · doi:10.1210/en.2012-1435 · Cited by 165
Mechanism of Cerebral β-Amyloid Angiopathy: Murine and Cellular Models
Herzig, M. C., Nostrand, W. E., & Jucker, M. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2006.tb00560.x · Cited by 169
Receptor-Mediated Endocytosis and Brain Delivery of Therapeutic Biologics
Xiao, G., & Gan, L.-S. (2013) · International Journal of Cell Biology · doi:10.1155/2013/703545 · Cited by 163
Interaction between blood-brain barrier and glymphatic system in solute clearance
Verheggen, I. C. M., Van Boxtel, M. P. J., Verhey, F. R. J., Jansen, J. F. A., & Backes, W. H. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.03.028 · Cited by 171
“Previously, it was thought that about 75 percent of Aβ was cleared by BBB transport, and only 10 percent by the glymphatic system (Shibata et al., 2000).”
BackgroundHamzé, R., Delangre, E., Tolu, S., Moreau, M., Janel, N., Bailbé, D., & Movassat, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315287 · Cited by 158
Failure of Perivascular Drainage of β‐amyloid in Cerebral Amyloid Angiopathy
Hawkes, C. A., Jayakody, N., Johnston, D. A., Bechmann, I., & Carare, R. O. (2014) · Brain Pathology · doi:10.1111/bpa.12159 · Cited by 163
“Aβ is absorbed into the blood by low-density lipoprotein receptor-related protein-1 (LRP) and P-glycoprotein, with α2-macroglobulin and apolipoprotein E also acting upon these pathways of clearance (7, 21, 68).”
BackgroundGrimm, M. O. W., Mett, J., Stahlmann, C. P., Haupenthal, V. J., Zimmer, V. C., & Hartmann, T. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00098 · Cited by 159
“…the blood-brain-barrier by the lipoprotein receptor-related protein (LRP) and by the P-glycoprotein efflux pump (pgP/MDR1/ABCB1) (Kang et al., 2000; Shibata et al., 2000; Lam et al., 2001), whereas the reentry of circulating Aβ from blood to brain is mainly mediated by RAGE (receptor for advanced…”
BackgroundJefferson, A. L., Beiser, A. S., Himali, J. J., Seshadri, S., O’Donnell, C. J., Manning, W. J., Wolf, P. A., Au, R., & Benjamin, E. J. (2015) · Circulation · doi:10.1161/circulationaha.114.012438 · Cited by 169
Blood–brain barrier alterations and their impact on Parkinson’s disease pathogenesis and therapy
Lau, K., Kotzur, R., & Richter, F. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00430-z · Cited by 187
“In aging rodents, LRP-1 expression is decreased [109].”
BackgroundCell‐specific blood–brain barrier regulation in health and disease: a focus on hypoxia
Engelhardt, S., Patkar, S., & Ogunshola, O. O. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12489 · Cited by 168
“The BBB regulates the entry of plasma-derived Aβ into the brain and clears brain-derived Aβ through the receptor for advanced glycation end-products (RAGE) and low-density lipoprotein receptorrelated protein respectively (Shibata et al., 2000; Deane et al., 2003).”
BackgroundAPOE modifies the association between Aβ load and cognition in cognitively normal older adults
Kantarci, K., Lowe, V., Przybelski, S. A., Weigand, S. D., Senjem, M. L., Ivnik, R. J., Preboske, G. M., Roberts, R., Geda, Y. E., Boeve, B. F., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31824365ab · Cited by 159
Sadowski, M. J., Pankiewicz, J., Scholtzova, H., Mehta, P. D., Prelli, F., Quartermain, D., & Wisniewski, T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604011103 · Cited by 167
Qosa, H., Abuznait, A. H., Hill, R. A., & Kaddoumi, A. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120319 · Cited by 159
“9 mm below the surface of the brain as previously reported [11].”
InfluentialDá Mesquita, S., Ferreira, A. C., Sousa, J. C., Correia-Neves, M., Sousa, N., & Marques, F. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.014 · Cited by 166
Gouveia-Freitas, K., & Bastos-Leite, A. J. (2021) · Neuroradiology · doi:10.1007/s00234-021-02718-7 · Cited by 159
“In the past decade, it also became apparent that pericytes are particularly important for the maintenance of BBB integrity [36, 37].”
BackgroundVogelgesang, S., Warzok, R., Cascorbi, I., Kunert-Keil, C., Schroeder, E., Kroemer, H., Siegmund, W., Walker, L., & Pahnke, J. (2004) · Current Alzheimer Research · doi:10.2174/1567205043332225 · Cited by 161
Brain cholesterol in normal and pathological aging
Martin, M., Dotti, C. G., & Ledesma, M. D. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.03.011 · Cited by 162
Human antibodies against amyloid β peptide: A potential treatment for Alzheimer's disease
Dodel, R., Hampel, H., Depboylu, C., Lin, S., Gao, F., Schock, S., Jäckel, S., Wei, X., Buerger, K., Höft, C., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10253 · Cited by 161
Smith, A. J., & Verkman, A. S. (2018) · The FASEB Journal · doi:10.1096/fj.201700999 · Cited by 157
“Abpeptides are cleared more rapidly than comparably sized dextrans (28, 43), suggesting the potentially limited importance of the paravascular clearance pathway for Ab clearance in the healthy brain (41).”
BackgroundQosa, H., Batarseh, Y. S., Mohyeldin, M. M., El Sayed, K. A., Keller, J. N., & Kaddoumi, A. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00190 · Cited by 156
Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer’s disease
Nicoll, J. A. R., Yamada, M., Frackowiak, J., Mazur-Kolecka, B., & Weller, R. O. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.003 · Cited by 160
“Impairment of the LRP-1-mediated transport of Aβ across the blood brain barrier will lead to CAA [38] Intriguingly, relevant studies have been performed involving study of clearance of A 40 from the brain following microinfusion [2].”
BackgroundImbalanced cholesterol metabolism in Alzheimer's disease
Xue-shan, Z., Peng, J., Wu, Q., Zhong, R., Li-hong, P., Tang, Z., Jiang, Z., Wang, G., & Liu, L. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.02.024 · Cited by 170
Immunotherapy for Alzheimer's disease
Gelinas, D. S., DaSilva, K., Fenili, D., St. George-Hyslop, P., & McLaurin, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404866101 · Cited by 157
Fryer, J. D., Taylor, J. W., DeMattos, R. B., Bales, K. R., Paul, S. M., Parsadanian, M., & Holtzman, D. M. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-21-07889.2003 · Cited by 160
“Clearance of A 40 from the brain has been suggested to occur via active transport across the blood– brain barrier (Ghersi-Egea et al., 1996; Shibata et al., 2000; Ji et al., 2001) as well as along peri-arterial interstitial fluid drainage pathways into cervical lymph nodes and then into peripheral circulation (Weller…”
BackgroundSelf-citationBarten, D. M., Guss, V. L., Corsa, J. A., Loo, A., Hansel, S. B., Zheng, M., Munoz, B., Srinivasan, K., Wang, B., Robertson, B. J., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.075408 · Cited by 159
“Unlike most peptides, A is actively transported from brain to plasma via lipoprotein related protein (Shibata et al., 2000) and from plasma to brain via the receptor for advanced glycation end products (Deane et al.”
BackgroundAlzheimer's disease and post-operative cognitive dysfunction
Xie, Z., & Tanzi, R. E. (2006) · Experimental Gerontology · doi:10.1016/j.exger.2006.01.014 · Cited by 159
Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier
Pan, W., Kastin, A. J., Zankel, T. C., van Kerkhof, P., Terasaki, T., & Bu, G. (2004) · Journal of Cell Science · doi:10.1242/jcs.01381 · Cited by 153
“One of the RAP receptors, LRP1, is abundantly expressed in brain microvessels in young mice (Shibata et al., 2000).”
BackgroundPeptide-Functionalized Lipid Nanoparticles for Targeted Systemic mRNA Delivery to the Brain
Han, E. L., Tang, S., Kim, D., Murray, A. M., Swingle, K. L., Hamilton, A. G., Mrksich, K., Padilla, M. S., Palanki, R., Li, J. J., et al. (2025) · Nano Letters · doi:10.1021/acs.nanolett.4c05186 · Cited by 158
Hartl, N., Adams, F., & Merkel, O. M. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000092 · Cited by 153
Amyloid-β immunisation for Alzheimer's disease
Wisniewski, T., & Konietzko, U. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70170-4 · Cited by 155
Role of Vascular Risk Factors and Vascular Dysfunction in Alzheimer's Disease
Dickstein, D. L., Walsh, J., Brautigam, H., Stockton, S. D., Gandy, S., & Hof, P. R. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20155 · Cited by 155
Castellano, J. M., Deane, R., Gottesdiener, A. J., Verghese, P. B., Stewart, F. R., West, T., Paoletti, A. C., Kasper, T. R., DeMattos, R. B., Zlokovic, B. V., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206446109 · Cited by 154
“(2000) Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain”
BackgroundResultSelf-citationSadowski, M., Pankiewicz, J., Scholtzova, H., Ripellino, J. A., Li, Y., Schmidt, S. D., Mathews, P. M., Fryer, J. D., Holtzman, D. M., Sigurdsson, E. M., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63355-x · Cited by 154
“The pharmacological targeting of apoE has to take into account that apoE is involved in the clearance of A from the central nervous system (CNS) across the BBB in addition to a role as a pathological chaperone.(75,76) ApoE KO mice and mice expressing human apoE4 on murine apoE KO background have impaired clearance of…”
BackgroundSelf-citationSiemers, E. R., Dean, R. A., Friedrich, S., Ferguson-Sells, L., Gonzales, C., Farlow, M. R., & May, P. C. (2007) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31805b7660 · Cited by 156
“Conversely, bulk flow of interstitial fluid is thought to be responsible for only 10% to 15% of A" clearance from the brain.(14) Consistent with these findings, imaging studies in squirrel monkeys using (123)I-labeled A" demonstrate a”
ResultLin, T.-W., Shih, Y.-H., Chen, S.-J., Lien, C.-H., Chang, C.-Y., Huang, T.-Y., Chen, S.-H., Jen, C. J., & Kuo, Y.-M. (2015) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2014.12.005 · Cited by 153
New Therapeutic Targets in the Neurovascular Pathway in Alzheimer's Disease
Zlokovic, B. V. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.011 · Cited by 151
“LRP Low density lipoprotein receptor related protein 1 (LRP), a member of the LDL receptor family, is a major clearance receptor for A at the BBB.(53) A binding to LRP is the first step in A clearance from brain mediated by transvascular A transport across the BBB (FIG.”
BackgroundInfluentialDysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders
Gil-Martins, E., Barbosa, D. J., Silva, V., Remião, F., & Silva, R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107554 · Cited by 152
Neurovascular Defects and Faulty Amyloid-β Vascular Clearance in Alzheimer's Disease
Sagare, A. P., Bell, R. D., & Zlokovic, B. V. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129037 · Cited by 140
“Reduced LRP1 levels in brain microves-sels correlate with endogenous A deposition in a (cid:1) cerebrovascular and brain accumulation in AD patients [102, 120].”
ApoE Deficiency Compromises the Blood Brain Barrier Especially After Injury
Methia, N., André, P., Hafezi-Moghadam, A., Economopoulos, M., Thomas, K. L., & Wagner, D. D. (2001) · Molecular Medicine · doi:10.1007/bf03401973 · Cited by 150
Neuroinflammation and anti-inflammatory therapy for Alzheimer’s disease
Moore, A. H., & O’Banion, M. K. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00162-x · Cited by 172
Carter, C. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.07.007 · Cited by 174
“, 2001) Exports amyloid/A2M complexes (Shibata et al., 2000) Cleaved by gamma secretase and BACE”
Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease
Weller, R. O., Preston, S. D., Subash, M., & Carare, R. O. (2009) · Alzheimer's Research & Therapy · doi:10.1186/alzrt6 · Cited by 144
“Absorption of Aβ into the blood, mediated by low-density lipoprotein receptor-related protein-1 (LRP-1) located in capillary endothelium [43,49], is a major mechanism for elimination of Aβ from the brain [43] and is six times faster than lymphatic drainage [50].”
BackgroundAlzheimer's disease: Effects of β-amyloid on mitochondria
Tillement, L., Lecanu, L., & Papadopoulos, V. (2011) · Mitochondrion · doi:10.1016/j.mito.2010.08.009 · Cited by 136
“2) resulting in the accumulation and aggregation of the peptide (Shibata et al., 2000).”
BackgroundSagare, A. P., Deane, R., & Zlokovic, B. V. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.008 · Cited by 143
“…degradation, it has been also reported that LRP1 transports several ligands transcellularly across the blood-brain barrier (BBB) including Aβ (Shibata et al., 2000; Deane et al., 2004a; Davis et al., 2004; Wu et al., 2005; Cirrito et al., 2005; Bell et al., 2007), RAP (Pan et al., 2004),…”
BackgroundMethodInfluentialLanz, T. A., Himes, C. S., Pallante, G., Adams, L., Yamazaki, S., Amore, B., & Merchant, K. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.048280 · Cited by 160
“On the other hand, central injections of A in mice and rats have been shown to diffuse fairly quickly into the blood and parenchymal vasculature (Ghersi-Egea et al., 1996; Shibata et al., 2000).”
BackgroundMačkić, J. B., Bading, J. R., Ghiso, J. A., Walker, L. C., Wısnıewskı, T., Frangione, B., & Zloković, B. V. (2002) · Vascular Pharmacology · doi:10.1016/s1537-1891(02)00198-2 · Cited by 158
Self-citationQosa, H., Abuasal, B. S., Romero, I. A., Weksler, B., Couraud, P.-O., Keller, J. N., & Kaddoumi, A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.01.023 · Cited by 146
Weller, R. O., Galea, I., Carare, R. O., & Minagar, A. (2010) · Pathophysiology · doi:10.1016/j.pathophys.2009.10.007 · Cited by 139
Li, J., Li, M., Ge, Y., Chen, J., Ma, J., Wang, C., Sun, M., Wang, L., Yao, S., & Yao, C. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00807-5 · Cited by 140
“The area was used to calibrate TEER: Ω/cm2 = Ω measurement/S, where S is the area of the bottom film of the board [37].”
MethodErickson, M. A., Hartvigson, P. E., Morofuji, Y., Owen, J. B., Butterfield, D. A., & Banks, W. A. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-150 · Cited by 145
“Other groups have shown LRP-1-dependent efflux of human forms of Aβ across the BBB [4,50], however, we have observed that murine Aβ1-42 also undergoes LRP-1-dependent BBB transport and is cleared at a faster rate across the murine BBB than human Aβ1-42 [7,51].”
BackgroundMethodInfluentialMitochondrial Alterations, Oxidative Stress and Neuroinflammation in Alzheimer's Disease
Verri, M., Pastoris, O., Dossena, M., Aquilani, R., Guerriero, F., Cuzzoni, G., Venturini, L., Ricevuti, G., & Bongiorno, A. I. (2012) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463201202500204 · Cited by 144
“beta (1-42) monomer absorbed to model phospholipid”
BackgroundRole of ABC Transporters in the Pathogenesis of Alzheimer’s Disease
Abuznait, A. H., & Kaddoumi, A. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300077c · Cited by 135
IL-4-Induced Selective Clearance of Oligomeric β-Amyloid Peptide1–42 by Rat Primary Type 2 Microglia
Shimizu, E., Kawahara, K., Kajizono, M., Sawada, M., & Nakayama, H. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.6503 · Cited by 143
“Transcytosis of A 1–40 across brain endothelium of the BBB, mediated by low-density lipoprotein receptor-related protein 1, was also thought to be an A 1–40 clearance route (39).”
BackgroundTherapeutic Potential of γ -Secretase Inhibitors and Modulators
Imbimbo, B. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608783334015 · Cited by 143
Storck, S. E., Hartz, A. M. S., Bernard, J., Wolf, A., Kachlmeier, A., Mahringer, A., Weggen, S., Pahnke, J., & Pietrzik, C. U. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.07.017 · Cited by 143
Holtzman, D. M. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:147 · Cited by 143
“Further, recent evidence suggests that apoE may contribute to this process through a receptor-mediated transport mechanism, Journal of Molecular Neuroscience Volume 17, 2001 in part via LRP (Shibata et al., 2000).”
BackgroundInfluentialSelf-citationGoulay, R., Romo, L. M., Hol, E. M., & Dijkhuizen, R. M. (2019) · Translational Stroke Research · doi:10.1007/s12975-019-00755-2 · Cited by 159
“between BBB clearance and ISF/CSF clearance decreases [50, 51].”
BackgroundWilson, M. R., Yerbury, J. J., & Poon, S. (2007) · Molecular BioSystems · doi:10.1039/b712728f · Cited by 142
“(4) The normally rapid removal of radiolabelled A from mouse brain is significantly inhibited by the LDL family inhibitor RAP and antibodies against LRP-1 and 2M.(115) Furthermore, when complexed with clusterin, the rate of clearance of A from the mouse brain across the BBB into plasma is increased by more than…”
Ren, H., Luo, C., Feng, Y., Yao, X., Shi, Z., Liang, F., Kang, J. X., Wan, J., Pei, Z., & Su, H. (2017) · The FASEB Journal · doi:10.1096/fj.201600896 · Cited by 133
“Both the blood-brain barrier transporters and the glymphatic system play important roles in interstitial Ab clearance (21, 38, 39).”
BackgroundJaeger, L. B., Dohgu, S., Hwang, M. C., Farr, S. A., Murphy, M. P., Fleegal-DeMotta, M. A., Lynch, J. L., Robinson, S. M., Niehoff, M. L., Johnson, S. N., et al. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1074 · Cited by 133
“Immunocytochemistry of brain microvessels from young (2 months) and old (9 months) C57BL/6 wild-type mice revealed that there is a 42% reduction in LRP-1 positive vessels in aged mice [13].”
LRP1 mediates bidirectional transcytosis of amyloid-β across the blood-brain barrier
Pflanzner, T., Janko, M. C., André-Dohmen, B., Reuss, S., Weggen, S., Roebroek, A. J. M., Kuhlmann, C. R. W., & Pietrzik, C. U. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.025 · Cited by 141
Little, K., Llorián‐Salvador, M., Scullion, S., Hernández, C., Simó‐Servat, O., del Marco, À., Bosma, E. K., Vargas-Soria, M., Carranza-Naval, M. J., Bergen, T. V., et al. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.10.008 · Cited by 152
A unifying hypothesis for Alzheimer's disease: from plaques to neurodegeneration
Edwards, F. A. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2019.03.003 · Cited by 140
“clearance of amyloidβ from the brain, for example across the blood-brain barrier[22].”
BackgroundAmyloid-beta transporter expression at the blood-CSF barrier is age-dependent
Pascale, C. L., Miller, M. C., Chiu, C., Boylan, M., Caralopoulos, I. N., Gonzalez, L., Johanson, C. E., & Silverberg, G. D. (2011) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-8-21 · Cited by 132
“These receptors bind a wide range of ligands, including Ab [42,43], and LRP-1 has been linked to AD [18,44,45].”
Wilhelmus, M. M. M., Otte-Höller, I., van Triel, J. J. J., Veerhuis, R., Maat-Schieman, M. L. C., Bu, G., de Waal, R. M. W., & Verbeek, M. M. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070050 · Cited by 138
“In several studies it has been demonstrated that transport from brain to blood is mediated by LRP-1 and vice versa by RAGE.(6,13,16,43) In normal brain, clearance of A is the net result of these counteractive mechanisms.”
BackgroundResultInfluentialMorikawa, M., Fryer, J. D., Sullivan, P. M., Christopher, E. A., Wahrle, S. E., DeMattos, R. B., O'Dell, M. A., Fagan, A. M., Lashuel, H. A., Walz, T., et al. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.11.005 · Cited by 126
Self-citationChen, F., Dong, R. R., Zhong, K. L., Ghosh, A., Tang, S. S., Long, Y., Hu, M. Y., Miao, M. X., Liao, J. M., Sun, H. B., et al. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.023 · Cited by 151
Extracellular amyloid formation and associated pathology in neural grafts
Meyer-Luehmann, M., Stalder, M., Herzig, M. C., Kaeser, S. A., Kohler, E., Pfeifer, M., Boncristiano, S., Mathews, P. M., Mercken, M., Abramowski, D., et al. (2003) · Nature Neuroscience · doi:10.1038/nn1022 · Cited by 116
“Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer’s disease.”
BackgroundPathophysiology of Alzheimer's Disease
Imbimbo, B. P., Lombard, J., & Pomara, N. (2005) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2005.09.009 · Cited by 156
Chen, X., Ghribi, O., & Geiger, J. D. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1376 · Cited by 132
“LRP-1), and increased Aβ influx (due to increased expression of RAGE) [5,59,62–64].”
BackgroundLipoprotein receptors – an evolutionarily ancient multifunctional receptor family
Dieckmann, M., Dietrich, M. F., & Herz, J. (2010) · Biological Chemistry · doi:10.1515/bc.2010.129 · Cited by 127
“…also be relevant for explaining the atheroprotective effect of locally, i.e., macrophage produced ApoE in the vascular wall (Linton et al., 1995; Shimano et al., 1995; Fazio et al., 1997; Yu et al., 2006). through its ligand binding domain by binding, sequestering or internalizing Wnt and BMP…”
Alzheimer's Disease: The Role of Microglia in Brain Homeostasis and Proteopathy
Clayton, K. A., Van Enoo, A. A., & Ikezu, T. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00680 · Cited by 134
“However, LRP1 expression in the BBB is reduced in rodents, primates, and humans (Shibata et al., 2000; Deane et al., 2004; Zerbinatti et al., 2004; Donahue et al., 2006).”
BackgroundBlood-brain barrier integrity in the pathogenesis of Alzheimer’s disease
Huang, Z., Wong, L.-W., Su, Y., Huang, X., Wang, N., Chen, H., & Yi, C. (2020) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2020.100857 · Cited by 126
Chiu, C., Miller, M. C., Monahan, R., Osgood, D. P., Stopa, E. G., & Silverberg, G. D. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.05.020 · Cited by 139
“…the low-density lipoprotein receptor-related protein 1 (LRP-1) and P-glycoprotein (P-gp), the two main Ab efflux transporters, and the receptor for advanced glycation end-products (RAGE, aka AGER), the main Ab influx transporter (Cirrito et al., 2005; Deane et al., 2003; Shibata et al., 2000).”
Holton, J. L., Lashley, T., Ghiso, J., Braendgaard, H., Vidal, R., Guerin, C. J., Gibb, G., Hanger, D. P., Rostagno, A., Anderton, B. H., et al. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.3.254 · Cited by 133
“The mechanisms by which Ab is cleared from the CNS have been studied (24, 25), but no data are yet available for ABri and ADan.”
BackgroundSelf-citationZerbinatti, C. V., Wozniak, D. F., Cirrito, J., Cam, J. A., Osaka, H., Bales, K. R., Zhuo, M., Paul, S. M., Holtzman, D. M., & Bu, G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0305803101 · Cited by 133
Self-citationInnate immunity receptor CD36 promotes cerebral amyloid angiopathy
Park, L., Zhou, J., Zhou, P., Pistick, R., El Jamal, S., Younkin, L., Pierce, J., Arreguin, A., Anrather, J., Younkin, S. G., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300021110 · Cited by 130
“Given that the effect of CD36 is restricted to Aβ1-40, it is unlikely that the attenuation is related to reduced Aβ cleavage from APP by secretases, because in that case reductions in both Aβ1-40 and Aβ1-42 would be anticipated (37).”
BackgroundInfluentialCrucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases
Choi, M. L., & Gandhi, S. (2018) · The FEBS Journal · doi:10.1111/febs.14587 · Cited by 127
Endothelial LRP1 protects against neurodegeneration by blocking cyclophilin A
Nikolakopoulou, A. M., Wang, Y., Ma, Q., Sagare, A. P., Montagne, A., Huuskonen, M. T., Rege, S. V., Kisler, K., Dai, Z., Körbelin, J., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20202207 · Cited by 130
Copper Exposure Perturbs Brain Inflammatory Responses and Impairs Clearance of Amyloid-Beta
Kitazawa, M., Hsu, H.-W., & Medeiros, R. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw081 · Cited by 134
“In humans, aging, the most prominent risk factor for AD, is known to decrease the brain LRP1 and LRP1-mediated transcytotic clearance of Aβ (Shibata et al., 2000; Silverberg, et al., 2010).”
BackgroundEffects of Ashwagandha (Roots of Withania somnifera) on Neurodegenerative Diseases
Kuboyama, T., Tohda, C., & Komatsu, K. (2014) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00022 · Cited by 127
Huang, M., Hu, M., Song, Q., Song, H., Huang, J., Gu, X., Wang, X., Chen, J., Kang, T., Feng, X., et al. (2015) · ACS Nano · doi:10.1021/acsnano.5b03124 · Cited by 127
The Role of Pericytes in Neurovascular Unit Remodeling in Brain Disorders
ElAli, A., Thériault, P., & Rivest, S. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15046453 · Cited by 122
“pericytes express the low density lipoprotein receptor-related protein 1 (LRP1), which is a transmembrane protein involved in Aβ processing and clearance through the BBB [89], thus suggesting an important role of pericytes in Aβ clearance [31].”
BackgroundMoura, R. P., Martins, C., Pinto, S., Sousa, F., & Sarmento, B. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1583205 · Cited by 125
Role of BACE1 in Alzheimer’s synaptic function
Das, B., & Yan, R. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0093-5 · Cited by 121
“ApoE can also impact Aβ accumulation through its receptor, as ApoE receptor knockout mice have shown to increase Aß accumulation due to reduced clearance [22].”
Wilhelmus, M. M. M., de Waal, R. M. W., & Verbeek, M. M. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0029-7 · Cited by 122
“complexes followed by degradation in lysosomes or transport into the plasma [4, 175].”
BackgroundPhosphorus Dendrimers Affect Alzheimer’s (Aβ1–28) Peptide and MAP-Tau Protein Aggregation
Wasiak, T., Йонов, М., Nieznański, K., Nieznańska, H., Klementieva, O. L., Granell, M., Cladera, J., Majoral, J., Caminade, A., & Klajnert‐Maculewicz, B. (2011) · Molecular Pharmaceutics · doi:10.1021/mp2005627 · Cited by 132
Is Alzheimer’s Disease a Liver Disease of the Brain?
Bassendine, M. F., Taylor-Robinson, S. D., Fertleman, M., Khan, M., & Neely, D. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-190848 · Cited by 124
“These include clearance via the glial-lymphatic (glymphatic) system [28] and transport across the BBB, mediated by lowdensity lipoprotein receptor-related peptide 1 (LRP1) [29, 30] and the low-density-lipoprotein receptor (LDLR).”
BackgroundColes, J. A., Myburgh, E., Brewer, J. M., & McMenamin, P. G. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.05.002 · Cited by 123
Current therapeutic targets for the treatment of Alzheimer’s disease
Grill, J. D., & Cummings, J. L. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.29 · Cited by 121
Spuch, C., Ortolano, S., & Navarro, C. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00269 · Cited by 107
“In this context, LRP1 and P-glycoprotein (P-gp) have been implicated in Aβ efflux (Shibata et al., 2000; Hartz et al., 2010; Katsouri and Georgopoulos, 2011).”
BackgroundCooper, J. M., Lathuiliere, A., Migliorini, M., Arai, A. L., Wani, M. M., Dujardin, S., Muratoglu, S. C., Hyman, B. T., & Strickland, D. K. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100715 · Cited by 122
“LRP1 is a central receptor that regulates trafficking and metabolism of several important molecules linked to AD, which include APP (22–24) and β-amyloid (27, 28), tau, and apoE (77, 78).”
BackgroundSelf-citationShinohara, M., Sato, N., Kurinami, H., Takeuchi, D., Takeda, S., Shimamura, M., Yamashita, T., Uchiyama, Y., Rakugi, H., & Morishita, R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.102277 · Cited by 117
Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties
Demeule, M., Beaudet, N., Régina, A., Besserer-Offroy, É., Murza, A., Tétreault, P., Belleville, K., Ché, C., Larocque, A., Thiot, C., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70647 · Cited by 116
“…broad parenchymal distribution of ANG2002 was also observed for other An2 conjugates (12–16) or kunitz-derived peptides (7), likely reflecting the extraordinarily high density of cerebral capillaries (57) as well as the broad distribution of LRP1 throughout the brain-capillary tree (58, 59).”
Soluble Arctic amyloid β protein inhibits hippocampal long‐term potentiation in vivo
Klyubin, I., Walsh, D. M., Cullen, W. K., Fadeeva, J. V., Anwyl, R., Selkoe, D. J., & Rowan, M. J. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03389.x · Cited by 115
Blasko, I., Jellinger, K. A., Kemmler, G., Krampla, W. W., Jungwirth, S., Wichart, I., Tragl, K. H., & Fischer, P. A. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.09.002 · Cited by 130
Metadata
- Authors
- Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., & Zlokovic, B. V.
- Affiliations
- University of Southern California (US)
- NYU Langone Health (US)
- Washington University in St. Louis (US)
- American Red Cross (US)
- University of Rochester Medicine (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2000-12-15
- Volume
- 106
- Issue
- 12
- Pages
- 1489-1499
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC387254
- OpenAlex
- W1997822484
- Cited by
- 1,413
- References
- 76
- Citations by year
- 2026: 38 · 2025: 60 · 2024: 58 · 2023: 59 · 2022: 57 · 2021: 75 · 2020: 85 · 2019: 73 · 2018: 52 · 2017: 67 · 2016: 64 · 2015: 56 · 2014: 60 · 2013: 62 · 2012: 60
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ag016223-04)
- National Institute on Aging (R37AG005891, R01AG013956, P50AG005142, AG16223, R37AG013956, AG05891)
- National Heart, Lung, and Blood Institute (R01HL050784)
- National Institute of Neurological Disorders and Stroke (NS 33466, R01NS038777)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Aβ40, Alzheimer's disease, blood-brain barrier, LDL receptor-related protein 1, receptor-associated protein, alpha2-macroglobulin, apolipoprotein E, amyloid-beta clearance, efflux transport, cerebral microvasculature, amyloid-beta deposition
- MeSH terms
- Aging, alpha-Macroglobulins, Alzheimer Disease, Amino Acid Sequence, Animals, Apolipoproteins E, Biological Transport, Blood-Brain Barrier, Brain, Catheterization, Genotype, Half-Life, Humans, Immunohistochemistry, Inulin, Iodine Radioisotopes, Kinetics, Male, Mice, Inbred C57BL, Molecular Sequence Data, Peptide Fragments, Receptors, Immunologic, Amyloid beta-Peptides, Mice, Knockout, Low Density Lipoprotein Receptor-Related Protein-1, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.






